HLA-DRB1 and myeloid sarcoma: HLA-DRB1*09:01-positive MS patients had lower ARR and FS scores of bowel and bladder function and had brainstem involvement less frequently than DRB1*09:01-negative patients (p = 0.047, 0.015 and 0.005, respectively) (Supplementary Table S8).